Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Endocyte (ECYT) Acquisition 'Transformative', Has Enough Cash Into 2020 - Cowen
-
UPDATE: Cowen Downgrades Endocyte (ECYT) to Market Perform, "Reprioritization To Earlier Stage Assets"
-
Cowen Reiterates Outperform Rating on Endocyte (ECYT); 'New SMDC Molecule May Modulate CAR T Activity, Improving Safety'
-
Endocyte to Present at the Cowen and Company 37th Annual Health Care Conference
-
Endocyte to Present at Upcoming Conferences
-
Endocyte to Present at Upcoming Conferences
-
Notable Analyst Rating Changes 9/9: (GCA) (NEM) (DHI) Upgraded; (DKS) (POT) (MDC) Downgraded
-
Endocyte (ECYT) Closes 5.18M Offering; Sees Net Proceeds of $101.8M
-
Endocyte, Inc. Closes Public Offering of Common Stock
-
Endocyte (ECYT) Prices 4.5M Share Offering at $21
-
Endocyte, Inc. Prices Public Offering of Common Stock
-
Endocyte (ECYT) Announces 4.5M Common Stock Offering
-
Endocyte to Present at Upcoming Conferences in March
-
Endocyte (ECYT) Files for $60M Cmmon Stock Offering
-
Cowen Starts Endocyte (ECYT) at Outperform

